Johnson & Johnson defied generic competition to post positive Q3 figures, including increases to both turnover and worldwide pharmaceutical sales.
Turnover rose 6.8% to approximately $16bn, whereas worldwide pharmaceutical sales increase 8.9% to $5.98bn.
Go deeper with GlobalData
The company’s biggest earner continued to be anti-inflammatory Remicade, with sales witnessing a 14.6% increase to $1.41bn.
The detrimental effect of generic competition wasn’t completely unfelt, however, as group net earnings fell 6.3% to $3.2bn and US sales fell 6.1%, with domestic sales of antipsychotic medication Risperdal only totalling $8m.
J&J’s Topamax and Procrit / Eprex medications also suffered at the hands of generics, with sales falling by 7.9% and 5.7% respectively.
